These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11195041)

  • 21. Proteinuria as a mediator of tubulointerstitial injury.
    Abbate M; Remuzzi G
    Kidney Blood Press Res; 1999; 22(1-2):37-46. PubMed ID: 10352406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Et and diabetic nephropathy: preclinical and clinical studies.
    Gagliardini E; Zoja C; Benigni A
    Semin Nephrol; 2015 Mar; 35(2):188-96. PubMed ID: 25966350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.
    Benigni A; Buelli S; Kohan DE
    Pediatr Nephrol; 2021 Apr; 36(4):763-775. PubMed ID: 32185491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelin in renal diseases and cardiovascular remodeling in renal failure.
    Orth SR; Viedt C; Amann K; Ritz E
    Intern Med; 2001 Apr; 40(4):285-91. PubMed ID: 11334385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of proteinuric renal disease and the emerging role of endothelin.
    Barton M
    Nat Clin Pract Nephrol; 2008 Sep; 4(9):490-501. PubMed ID: 18648345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension.
    Rothermund L; Kossmehl P; Neumayer HH; Paul M; Kreutz R
    J Hypertens; 2003 Dec; 21(12):2389-97. PubMed ID: 14654760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of endothelin receptor antagonism in kidney disease.
    Czopek A; Moorhouse R; Webb DJ; Dhaun N
    Am J Physiol Regul Integr Comp Physiol; 2016 Mar; 310(5):R388-97. PubMed ID: 26702154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.
    Remuzzi G; Ruggenenti P; Perico N
    Ann Intern Med; 2002 Apr; 136(8):604-15. PubMed ID: 11955029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-angiotensin system blockade alone or combined with ET
    Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
    Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
    Ruggenenti P; Perna A; Loriga G; Ganeva M; Ene-Iordache B; Turturro M; Lesti M; Perticucci E; Chakarski IN; Leonardis D; Garini G; Sessa A; Basile C; Alpa M; Scanziani R; Sorba G; Zoccali C; Remuzzi G;
    Lancet; 2005 Mar 12-18; 365(9463):939-46. PubMed ID: 15766995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives.
    Tylicki L; Larczynski W; Rutkowski B
    Kidney Blood Press Res; 2005; 28(4):230-42. PubMed ID: 16127280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.
    Suzuki Y; Lopez-Franco O; Gomez-Garre D; Tejera N; Gomez-Guerrero C; Sugaya T; Bernal R; Blanco J; Ortega L; Egido J
    Am J Pathol; 2001 Nov; 159(5):1895-904. PubMed ID: 11696450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking?
    Benigni A; Remuzzi G
    Nephrol Dial Transplant; 1998 Nov; 13(11):2734-8. PubMed ID: 9829469
    [No Abstract]   [Full Text] [Related]  

  • 36. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist.
    Zoja C; Donadelli R; Corna D; Testa D; Facchinetti D; Maffi R; Luzzana E; Colosio V; Bertani T; Remuzzi G
    Am J Kidney Dis; 1997 Feb; 29(2):254-64. PubMed ID: 9016898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin receptor blockers: RAAS blockade and renoprotection.
    Ruilope LM
    Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex-Specific Effect of Endothelin in the Blood Pressure Response to Acute Angiotensin II in Growth-Restricted Rats.
    Intapad S; Ojeda NB; Varney E; Royals TP; Alexander BT
    Hypertension; 2015 Dec; 66(6):1260-6. PubMed ID: 26459423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelin in chronic proteinuric kidney disease.
    Gagliardini E; Buelli S; Benigni A
    Contrib Nephrol; 2011; 172():171-184. PubMed ID: 21893998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?
    Lewington AJ; Arici M; Harris KP; Brunskill NJ; Walls J
    Nephrol Dial Transplant; 2001 May; 16(5):885-8. PubMed ID: 11328889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.